Summarized by Masters of Longevity from Longevity Technology.
An article about AI-designed drug discovery that explains a preclinical candidate and the preclinical experiments and safety checks readers will find inside.
Key Takeaways
- Insilico nominated ISM9546 as a preclinical oral VAV1 molecular glue degrader for autoimmune indications.
- In an animal colitis model histopathology scores improved by roughly 60% versus control after treatment.
- Short 14-day toxicity studies in rodents and nonhuman primates showed favorable safety and low brain exposure.
